O
ENGN icon

OrbiMed’s enGene Therapeutics ENGN Stock Holding History

OrbiMed’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-677,977
Closed -$2.47M – 116
2025
Q2 		$2.47M Sell
677,977
-213,639
-24% -$802K 0.06% 85
2025
Q1 		$3.99M Sell
891,616
-28,723
-3% -$178K 0.1% 82
2024
Q4 		$6.12M Buy
+920,339
New +$7.15M 0.13% 81

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

OrbiMed's ENGN Position: Q3 2025 in Review

OrbiMed sold out of enGene Therapeutics (ENGN) in Q3 2025, closing a stake of 677,977 shares — an estimated $2.47M sold.

OrbiMed first reported a position in ENGN in Q4 2024 and held it in 3 quarters. The position peaked at $6.12M in Q4 2024. 37 funds tracked by Wall St. Rank hold ENGN as of Q3 2025.

  • OrbiMed reported no remaining enGene Therapeutics position as of Q3 2025 after selling out during the quarter.
  • OrbiMed sold 677,977 enGene Therapeutics shares in Q3 2025, an estimated $2.47M.
  • OrbiMed first reported a position in enGene Therapeutics in Q4 2024 and held it in 3 quarters.
  • OrbiMed's enGene Therapeutics position peaked at $6.12M in Q4 2024.
  • 37 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2025.

Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.